1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Von Willebrand Disease - Pipeline Review, H1 2013

Von Willebrand Disease - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 40 pages

Von Willebrand Disease - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Von Willebrand Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Von Willebrand Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Von Willebrand Disease. Von Willebrand Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Von Willebrand Disease.
- A review of the Von Willebrand Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Von Willebrand Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Von Willebrand Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Von Willebrand Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Von Willebrand Disease - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Von Willebrand Disease Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Von Willebrand Disease 7
Von Willebrand Disease Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Von Willebrand Disease Therapeutics - Products under Development by Companies 13
Companies Involved in Von Willebrand Disease Therapeutics Development 14
Baxter International Inc. 14
Glenmark Pharmaceuticals Ltd. 15
Pfizer Inc. 16
CSL Limited 17
Von Willebrand Disease - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
beroctocog alfa - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
beroctocog alfa - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
oprelvekin - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
GBR-600 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
vonicog alfa - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Von Willebrand Disease Therapeutics - Drug Profile Updates 30
Von Willebrand Disease Therapeutics - Dormant Products 32
Von Willebrand Disease - Product Development Milestones 33
Featured News and Press Releases 33
May 30, 2013: CSL Behring Receives CHMP Positive Opinion For Voncento For Prevention And Treatment Of Bleeding In Patients With Haemophilia A And Von Willebrand Disease 33
Oct 13, 2011: Baxter Initiates Phase III Trial Of Investigational BAX 111 For Treatment Of von Willebrand Disease 34
Dec 06, 2010: Baxter Reports Interim Data From Phase I Combination Study Of rVWF In von Willebrand Disease 34
Apr 14, 2010: Baxter Marks World Hemophilia Day by Reaffirming Ongoing Commitment to Partnering with Community to Raise Standard of Hemophilia Care Around the World 35
Feb 04, 2010: CSL Behring Announces That Global SWIFT Studies Will Evaluate Safety And Efficacy Of Biostate For Von Willebrand Disease And Hemophilia A 36
Dec 11, 2006: Baxter Announces Therapeutic Development Program for First Blood-Free Recombinant Von Willebrand Factor 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables


Number of Products Under Development for Von Willebrand Disease, H1 2013 7
Products under Development for Von Willebrand Disease - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Baxter International Inc., H1 2013 14
Glenmark Pharmaceuticals Ltd., H1 2013 15
Pfizer Inc., H1 2013 16
CSL Limited, H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 22
Von Willebrand Disease Therapeutics - Drug Profile Updates 30
Von Willebrand Disease Therapeutics - Dormant Products 32

List of Figures


Number of Products under Development for Von Willebrand Disease, H1 2013 7
Products under Development for Von Willebrand Disease - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 18
Assessment by Route of Administration, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Molecule Type, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Diabetes & Obesity Drug Development Pipeline Review, 2016

Diabetes & Obesity Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Diabetes & Obesity Drug Development Pipeline Review, 2016 Summary The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type ...

Ophthalmology Drug Development Pipeline Review, 2016

Ophthalmology Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Ophthalmology Drug Development Pipeline Review, 2016 Summary Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, ...

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H2 2016

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.